Potentiation and Inhibition of bFGF Binding by Heparin: A Model for Regulation of Cellular Response
- 22 January 2000
- journal article
- research article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 39 (6), 1434-1445
- https://doi.org/10.1021/bi991895z
Abstract
Basic fibroblast growth factor (bFGF) binds to cell surface tyrosine kinase receptor proteins and to heparan sulfate proteoglycans. The interaction of bFGF with heparan sulfate on the cell surface has been demonstrated to impact receptor binding and biological activity. bFGF receptor binding affinity is reduced on cells that do not express heparan sulfate. The addition of soluble heparin or heparan sulfate has been demonstrated to rescue the bFGF receptor binding affinity on heparan sulfate deficient cells yet has also been shown to inhibit binding under some conditions. While the chemical requirements of the heparin−bFGF−receptor interactions have been studied in detail, the possibility that heparin enhances bFGF binding in part by physically associating with the cell surface has not been fully evaluated. In the study presented here, we have investigated the possibility that heparin binding to the cell surface might play a role in modulating bFGF receptor binding and activity. Balb/c3T3 cells were treated with various concentrations of sodium chlorate, so as to express a range of endogenous heparan sulfate sites, and [125I]bFGF binding was assessed in the presence of a range of heparin concentrations. Low concentrations of heparin (0.1−30 nM) enhanced bFGF receptor binding to an extent that was inversely proportional to the amount of endogenous heparan sulfate sites present. At high concentrations (10 μM), heparin inhibited bFGF receptor binding in cells under all conditions. The ability of heparin to stimulate and inhibit bFGF−receptor binding correlated with altered bFGF-stimulated tyrosine kinase activity and cell proliferation. Under control and chlorate-treated conditions, [125 I]heparin was observed to bind with a high affinity to a large number of binding sites on the cells (Kd = 57 and 50 nM with 3.5 × 106 and 3.6 × 106 sites/cell for control and chlorate-treated cells, respectively). A mathematical model of this process revealed that the dual functions of heparin in bFGF binding were accurately represented by heparin cell binding-mediated stimulation and soluble heparin-mediated inhibition of bFGF receptor binding.Keywords
This publication has 22 references indexed in Scilit:
- Engineering epidermal growth factor for enhanced mitogenic potencyNature Biotechnology, 1996
- Basic Fibroblast Growth Factor Binds Its Receptors, Is Internalized, and Stimulates DNA Synthesis in Balb/c3T3 Cells in the Absence of Heparan SulfateJournal of Biological Chemistry, 1996
- Receptor-mediated effects on ligand availability influence relative mitogenic potencies of epidermal growth factor and transforming growth factor αJournal of Cellular Physiology, 1996
- Multivalent Ligand-Receptor Binding Interactions in the Fibroblast Growth Factor System Produce a Cooperative Growth Factor and Heparin Mechanism for Receptor DimerizationBiochemistry, 1994
- Heparan sulphate: Functional role as a modulator of fibroblast growth factor activityBiochemical Society Transactions, 1993
- Repression of myogenic differentiation by aFGF, bFGF, and K-FGF is dependent on cellular heparan sulfate.The Journal of cell biology, 1992
- Turnover of Functional Basic Fibroblast Growth Factor Receptors on the Surface of BHK and NIH 3T3 CellsGrowth Factors, 1990
- High and low affinity binding sites for basic fibroblast growth factor on cultured cells: Absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cellsJournal of Cellular Physiology, 1987
- Heparin protects basic and acidic FGF from inactivationJournal of Cellular Physiology, 1986
- LSODE and LSODI, two new initial value ordinary differential equation solversACM SIGNUM Newsletter, 1980